by Combat Cancer | Jun 8, 2024 | News
Combat Medical’s HIVEC® (recirculating hyperthermic intravesical chemotherapy) system, utilising mitomycin C (MMC), offers a compelling alternative to Bacillus Calmette-Guérin (BCG) for treating high-risk, non-muscle-invasive bladder cancer (NMIBC). As a...
by Combat Cancer | Jun 1, 2024 | News
New HIVEC®-HEAT Phase 3 trial for bladder cancer could be a game-changer forpatients with BCG-unresponsive nonmuscle-invasive bladder cancer Combat Medical has entered into partnership with the University of Leicester, England, to run aphase 3 trial of its HIVEC®...
by Combat Cancer | May 25, 2024 | News
Bladder cancer is the seventh most commonly diagnosed solid tumour worldwide, with around 75% of cases being non-muscle-invasive. Despite its prevalence, awareness about its signs and symptoms remains alarmingly low. A recent patient survey conducted by the World...
by Combat Cancer | May 23, 2024 | News
May 23 2024 – Combat Medical has entered into partnership with the University of Leicester, England, to run a phase 3 trial of its HIVEC® treatment for BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) as an alternative to radical cystectomy. HIVEC®-HEAT...
by Combat Cancer | May 17, 2024 | News
Bladder cancer is a significant health concern, and while it is often considered a disease that predominantly affects men, women face unique and challenging obstacles in its diagnosis and treatment. One of the most common symptoms of bladder cancer is haematuria....
Recent Comments